REGENXBIO Inc.

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. If you purchased REGENXBIO securities and suffered losses, click here to join the investigation.

Name

This field is for validation purposes and should be left unchanged.

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.

Name(Required)

First Last

Email(Required)

Phone(Required)

Estimated Losses(Required)

Where did you see our press release?(Required)

If you selected 'Other' above, please specify below:(Required)

Would you like to receive future case and securities updates from Johnson Fistel, PLLP via email?(Required)

Yes

Would you like to receive information about Johnson Fistel, PLLP's free portfolio monitoring service?(Required)

Yes

By selecting yes, I agree to receive marketing text messages and calls from Johnson Fistel, PLLP at the phone number provided. I understand these messages may be sent using an automatic dialing system, that consent is not a condition of purchase or receipt of services, and that message & data rates may apply. I can reply HELP for help or STOP to cancel. See our Privacy Policy and Terms.(Required)

Yes

By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, PLLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

I Agree

Why Is Johnson Fistel Investigating REGENXBIO?

On August 24, 2026, REGENXBIO disclosed that the FDA placed its RGX-121 gene therapy program on clinical hold after expanded MRI monitoring identified abnormalities in the spine scans of five clinical trial participants. The Company stated that the monitoring program had been implemented months earlier following a clinical hold involving a related gene therapy and that it no longer expects to resubmit its application for FDA approval in the near term. Previously, REGENXBIO had represented that existing clinical data were sufficient, no additional studies were required, and the application remained on track for resubmission during the third quarter of 2026. The Company also completed a July 2026 public offering that generated approximately $107.8 million in estimated net proceeds. Following the August 24 disclosure, REGENXBIO shares declined more than 24% in premarket trading. Johnson Fistel is investigating whether the Company misrepresented or failed to disclose material information concerning its expanded monitoring program, regulatory risks, and anticipated application timeline.

If you purchased REGENXBIO securities and suffered losses, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471. There is no cost or obligation to you.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights

Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder litigation involving securities fraud, breaches of fiduciary duties, and other violations of state and federal law.

Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.

Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. This press release may be considered a promotional communication. The attorney responsible for this communication is Frank J. Johnson.

Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471
jimb@johnsonfistel.com | fjohnson@johnsonfistel.com

Don’t Miss Key Updates on Your Stock Holdings!

Join JF Alerts. We’ll send you timely updates regarding our cases and investigations.

It’s free. No cost, no obligation. Unsubscribe at any time.

We respect your privacy. Johnson Fistel, PLLP does not share your information with others.

The submission of this form does not establish an attorney-client relationship with Johnson Fistel, PLLP.